| Accession |
PRJCA010692 |
| Title |
Phase I clinical study of fluzoparib combined with apatinib in the treatment of ovarian cancer or triple-negative breast cancer |
| Relevance |
Medical |
| Data types |
clinical, image ,Metabolic ,Biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
Objective: To evaluate the safety tolerance of fluzoparib combined with apatinib in the treatment of ovarian cancer or triple-negative breast cancer.To determine the recommended dose (RP2D) for a phase II trial of fluzoparib plus apatinib.Secondary study objectives: To evaluate the efficacy of fluzoparib combined with apatinib in the treatment of ovarian cancer or triple-negative breast cancer.To observe the pharmacokinetic (PK) characteristics of fluzoparib combined with apatinib in the treatment of ovarian cancer or triple-negative breast cancer.To preliminarily explore the correlation between patient biomarkers and clinical efficacy. |
| Sample scope |
Multiisolate |
| Release date |
2022-07-21 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Jiangsu Hengrui Pharmaceutical Co. LTD
|
|
FZPL-I-104-OC/BC
|
Phase I clinical study of fluzoparib combined with apatinib in the treatment of ovarian cancer or triple-negative breast cancer
|
|
|
| Submitter |
luchongyang
chongyang
lu (chongyang.lu@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2022-07-21 |
